A Double-Blind, Placebo Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects With Progressive Supranuclear Palsy

Trial Profile

A Double-Blind, Placebo Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects With Progressive Supranuclear Palsy

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Jul 2017

At a glance

  • Drugs C2N 8E12 (Primary)
  • Indications Progressive supranuclear palsy
  • Focus Adverse reactions
  • Sponsors C2N Diagnostics
  • Most Recent Events

    • 20 Jul 2017 Results presented at the Alzheimer's Association International Conference 2017.
    • 08 Jun 2017 Results presented at the 21st International Congress of Parkinson's Disease and Movement Disorders.
    • 09 Dec 2016 According to a C2N Diagnostics media release, results of this study are guiding the design of phase 2 studies in subjects with Alzheimer's disease (CTP 275868) and progressive supranuclear palsy (CTP 279539).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top